

Anti-Amyloid Beta Antibody (Donanemab)

Introduction

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody targeting the N-terminal pyroglutamate epitope of amyloid β (A β). Donanemab has the potential to be used in early Alzheimer's disease research.

Product parameters

Alternative Names	LY3002813-SC, LY3002813-IV
Target Accession	P05067
Target	Amyloid Beta
CAS number	1931944-80-7
Molecular Weight	145.36 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

